| 4.8 0.01 (0.21%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7 |
1-year : | 7.96 |
| Resists | First : | 5.99 |
Second : | 6.82 |
| Pivot price | 5.76 |
|||
| Supports | First : | 4.65 |
Second : | 3.87 |
| MAs | MA(5) : | 5.27 |
MA(20) : | 5.78 |
| MA(100) : | 5.12 |
MA(250) : | 4.8  |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 3.3 |
D(3) : | 13 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 7.67 | Low : | 3.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ WVE ] has closed below the lower bollinger band by 3.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 11.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.87 - 4.9 | 4.9 - 4.93 |
| Low: | 4.58 - 4.62 | 4.62 - 4.66 |
| Close: | 4.74 - 4.8 | 4.8 - 4.86 |
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Tue, 16 Apr 2024
Wave Life Sciences (NASDAQ:WVE) Trading Down 4.9% - MarketBeat
Mon, 15 Apr 2024
SG Americas Securities LLC Has $175000 Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Tue, 09 Apr 2024
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth - Simply Wall St
Wed, 27 Mar 2024
Wave Life Sciences to Present at Upcoming Investor Conferences - GlobeNewswire
Fri, 22 Mar 2024
WVE Stock Quote Price and Forecast - CNN
Sat, 09 Mar 2024
Wave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.2228e+008 (%) |
| Held by Institutions | 6.725e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.55 |
| Profit Margin | -50.8 % |
| Operating Margin | -64.4 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.1331e+008 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.3e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -8.89 |
| Price to Sales | 2.60411e+006 |
| Price to Cash Flow | 0 |
| Dividend | 3.59e+006 |
| Forward Dividend | 2.98e+006 |
| Dividend Yield | 74791700% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|